Cardiac Output Monitoring Devices Market (Technology: Pulmonary Artery Catheter, Thermodilution Pulse Contour Analysis Technique, Lithium Dilution Technique, Arterial Waveform Analysis Techniques, Doppler, Transthoracic Impedance & Bioreactance Analysis, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Cardiac Output Monitoring Devices market size was valued at USD 1.20 billion in 2021 and is predicted to hit USD 2.1 billion by 2030 with a registered CAGR of 4.20% during the forecast period 2022 to 2030.

Cardiac output is the volume of blood pumped by the right or left ventricle of the heart per minute. It is dependent on heart rate and stroke volume. Methods of cardiac output monitoring are based on bioimpedance, pulse contour analysis, thermodilution, FloTrac monitoring, PiCCO cardiac output monitoring, Doppler, and Ficks principle. Usage of cardiac output monitoring devices is a significant aspect of evaluating patients in the critical care unit, operating theatre, and elsewhere. Technological advancements have enabled continuous real-time cardiac output (CO) monitoring using lithium dilution technique. This technique is expected to witness exponential growth in the cardiac output monitoring devices market during the forecast period. Lithium dilution (LiD) exhibits good correlation with the pulmonary artery catheter (PAC) thermodilution technique in hyperdynamic conditions. This trend has helped manufacturers in the cardiac output monitoring devices market to leverage opportunities in lithium dilution and PAC thermodilution techniques. Hence, LiDCOplus technology is being used as a reliable substitute for more invasive PAC thermodilution methods. Rise in trend of using minimally invasive cardiac output monitoring (MICOM) devices is driving the global cardiac output monitoring devices market size. Cardiac output monitoring devices analysis has led to innovations in less-invasive Doppler ultrasound.

The global cardiac output monitoring devices market is witnessing increase in adoption of less-invasive methods for measuring stroke volume (SV) and cardiac output in patients. Transthoracic electrical bioimpedance (TEB) and Doppler echocardiography (transthoracic echocardiography) are non-invasive methods used for the measurement of SV and CO. Invasive devices account for the largest share of the global cardiac output monitoring devices market in terms of revenue; however, large numbers of healthcare providers are opting for non-invasive methods to improve the quality of life of patients. The need for innovative methods to assess flow-based hemodynamic parameters such as SV in patients is rising. Healthcare providers in the cardiac output monitoring devices market landscape are increasing efforts to assess SV in patients, as it provides vital insights into systemic oxygen delivery and global tissue perfusion.

Report Scope of the Cardiac Output Monitoring Devices Market

COVID-19 Impact on Cardiac Output Monitoring Devices Market

The COVID-19 pandemic has had a negative impact on the global cardiac output monitoring devices market. Governments of affected countries deferred non-essential surgeries and patient visits during the breakout year of the pandemic. This led to substantial decline in overall non-emergency surgery and treatments, thereby limiting the cardiac output monitoring devices market growth. Key market players reported decline in revenue due to the pandemic. However, the market has been recovering due to easing of restrictions by countries across the globe.

Technological Advancements Driving Transthoracic Impedance & Bioreactance Analysis Segment

In terms of technology, the transthoracic impedance & bioreactance analysis segment is projected to grow at the fastest CAGR during the forecast period. Transthoracic impedance & bioreactance measures the ‘phase shift’ of pulses of alternating current passed through the body using three electrodes. The bioreactance method estimates cardiac output by analyzing the frequency of relative phase shift of electronic current across the thorax. This approach results in improved precision of the bioreactance system as demonstrated by a 100-fold larger signal-to-noise ratio than that of bioimpedance, making it less susceptible to interference from adipose tissue, electrode placement, and excessive movement. Thoracic bioimpedance is a non-invasive method to measure cardiac output. Large numbers of validation studies are carried out using this technique. This is anticipated to drive the segment during the forecast period. Moreover, rise in trend of non-invasive continuous cardiac output measurement among healthcare professionals is anticipated to drive the segment in the next few years.

Increase in Prevalence of Cardiac Diseases Propelling Consumables & Accessories Segment

The consumables & accessories segment held the largest share of the global market in terms of revenue in 2021. The segment is anticipated to dominate the global market owing to the rise in prevalence of cardiac diseases and demand for consumables. End-users enter into rental agreements with manufacturers to install cardiac output monitoring devices at their facilities. According to the terms of the agreement, end-users need to purchase disposables to operate these devices. Hence, increase in installation base of cardiac output monitoring devices and rise in prevalence of cardiovascular diseases across the globe are likely to augment the usage of consumables during the forecast period.

Safety, Accuracy, and Reproducible Results Bolstering Invasive Segment

In terms of type, the invasive segment held significant share of the global market in 2021. Invasive cardiac output monitoring devices are ideal for continuous cardiac output monitoring, as these devices are safe, accurate, and provide reproducible results. Minimally invasive cardiac output monitoring devices provide real-time, beat-to-beat cardiac output, preload, and afterload. Increase in usage of minimally invasive technique with central venous lines and arterial lines is likely to drive the segment during the forecast period. Thus, high number of cardiac surgeries procedures performed annually, rise in demand for minimally invasive cardiac output monitoring, and development of non-invasive cardiac output monitoring devices are propelling the segment.

Rise in Investments in Advanced Medical Devices Driving Hospitals Segment

In terms of end-user, the hospitals segment held major share of the global market in 2021. Cardiac disorders are primarily treated in hospitals. Rise in number of hospitals and increase in patient preference to obtain treatment in hospitals are projected to propel the segment during the forecast period. The segment is likely to be driven by the increase in investments in hospitals for advanced medical devices. Government initiatives in developing health care infrastructure through public hospitals are also expected to drive the segment.

Regional Outlook of Global Cardiac Output Monitoring Devices Market

North America accounted for the largest share of the global cardiac output monitoring devices market in 2021. This can be ascribed to the increase in incidence of CVDs, rise in healthcare expenditure, surge in disposable income, growth in health awareness, and availability of technologically advanced devices in the region. According to the Population Reference Bureau, the geriatric population in the U.S. is projected to increase from 52.9 million in 2018 to 95 million by 2060. The geriatric population is likely to constitute 23.10% of the total population of the U.S. in 2060 as against 16.8% in 2018.

The market in Asia Pacific is likely to grow at the fastest CAGR from 2022 to 2030. Asia Pacific is witnessing gradual adoption of novel products, increase in health care expenditure, and changes in dynamics in the in vitro diagnostics industry. This is leading to a rise in adoption of new technologies in hospitals and diagnostic laboratories in the region.

Key Developments in Global Cardiac Output Monitoring Devices Market

• In November 2021, Philips announced the acquisition of Cardiologs, a France-based medical technology company. The acquisition is expected to strengthen Philips' existing cardiac diagnostics and monitoring portfolio with Cardiologs' innovative software technology, electrocardiogram (ECG) analysis, and reporting services.
• In November 2021, GE Healthcare announced the launch of a modular, scalable CT platform. The Revolution Apex platform is the first computed tomography (CT) platform with built-in scalability for onsite CT detector upgrades from 40 mm to 80 mm or 160 mm detector coverage without having to replace the gantry. The new Revolution Apex platform has the quickest gantry speed in the world, with 0.23 seconds per rotation and 19.5-millisecond effective temporal resolution to freeze cardiac action.
• In July 2020, Abbott Laboratories announced that the U.S. Food and Drug Administration (FDA) had approved its next-generation Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices
• In 2019, ZOLL Medical, an Asahi Kasei Group Company, acquired Cardiac Science, a leading provider of automated external defibrillators (AEDs), related services, and accessories. The acquisition strengthened ZOLL Medical’s position in the AED segment.
• In 2018, BIOTRONIK became the exclusive U.S. distributor for InfoBionic’s MoMe Kardia external cardiac diagnostic monitor. This helped the company expand its product portfolio of cardiovascular solutions to support physicians in providing the best care as fast and efficiently as possible.

Some of the prominent players in the Cardiac Output Monitoring Devices Market include:

• GE Healthcare
• Getinge AB
• Edward Lifesciences Corporation
• Baxter International, Inc.
• LiDCO Group plc
• ICU Medical, Inc.
• Deltex Medical Group plc
• Uscom
• CNSystems Medizintechnik GmbH

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cardiac Output Monitoring Devices market

• Technology
• Pulmonary Artery Catheter
• Thermodilution Pulse Contour Analysis Technique
• Lithium Dilution Technique
• Arterial Waveform Analysis Technique
• Doppler
• Transthoracic Impedance & Bioreactance Analysis
• Product
• Consumables & Accessories
• Devices
• Type
• Invasive
• Non-invasive
• End-user
• Hospitals
• Ambulatory Surgical Centers
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Cardiac Output Monitoring Devices industry analysis from 2022 to 2030 to identify the prevailing Cardiac Output Monitoring Devices industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Cardiac Output Monitoring Devices industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Cardiac Output Monitoring Devices industry trends, key players, market segments, application areas, and market growth strategies.